Roche Reports Results of Ocrevus (ocrelizumab) in Three P-III Studies for Relapsing and Primary Progressive Multiple Sclerosis

Shots:

• The P-III OPERA, ORATORIO and OBOE studies result involves assessing of Ocrevus (ocrelizumab) vs PBO in patients with RMS and PPMS, presented at AAN Annual Meeting
• Results: reduction in risk of disability progression associated with exposure and lower B-cell levels & permanent disability progression; @24wks. reduction in CDP; @48wks. RMS, PPMS patients with CDP treated with Ocrevus vs switched to Ocrevus, (10.4 %, 43.7% vs 15.7%, 53.1%); @12, 24 & 52 wks. in RMS reduction in nerve cell damage, inflammation biomarker in serum and CSF
• Ocrevus (ocrelizumab, IV) is a mAb targeting CD20+ B cells, administered every 6mos. and is approved in 85 countries including NA, SA, Eastern Europe & EU for both RMS & PPMS

Click here to read full press release/ article | Ref: Roche | Image: Tam Tam Phuong